FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Francesco Makovec

Research Profile

Living Beings

Chemicals & Drugs

Concepts & Ideas

Genes & Molecular Sequences

Molecular Structure

Anatomy

Co-author Network

Publications

TOP 3
Andrea Cappelli; Alessandra Concas; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Antonio Giordani; Gianluca Giorgi; Germano Giuliani; Francesco Makovec; Marco Paolino; Patrizia Porcu; Luigi Piero Stasi; Salvatore Valenti; Salvatore Vomero; Maurizio Anzini; Giulia Bini; Giovanni Biggio
Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold.
Michela V Pavan; Giorgio Stefancich; Federico Berti; Alessia Ciogli; Chantal Escrieut; Flora Ferrari; Daniel Fourmy; Francesco Gasparrini; Lucia Lassiani; Francesco Makovec; Esther Marco; Laura Mennuni; Antonio Varnavas
New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R).
Mariangela Biava; Giulio Cesare Porretta; Giovanna Poce; Claudio Battilocchio; Maurizio Botta; Fabrizio Manetti; M Rovini; Andrea Cappelli; Lidia Sautebin; Antonietta Rossi; Carlo Pergola; Carla Ghelardini; N Galeotti; Francesco Makovec; A Giordani; P Anzellotti; S Tacconelli; Paola Patrignani; Maurizio Anzini
Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Francesco Makovec (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Andrea Cappelli; Alessandra Concas; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Antonio Giordani; Gianluca Giorgi; Germano Giuliani; Francesco Makovec; Marco Paolino; Patrizia Porcu; Luigi Piero Stasi; Salvatore Valenti; Salvatore Vomero; Maurizio Anzini; Giulia Bini; Giovanni Biggio
Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold.
Journal of medicinal chemistry 2011;54(20):7165-75.
2011: Michela V Pavan; Giorgio Stefancich; Federico Berti; Alessia Ciogli; Chantal Escrieut; Flora Ferrari; Daniel Fourmy; Francesco Gasparrini; Lucia Lassiani; Francesco Makovec; Esther Marco; Laura Mennuni; Antonio Varnavas
New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R).
Journal of medicinal chemistry 2011;54(16):5769-85.
2011: Mariangela Biava; Giulio Cesare Porretta; Giovanna Poce; Claudio Battilocchio; Maurizio Botta; Fabrizio Manetti; M Rovini; Andrea Cappelli; Lidia Sautebin; Antonietta Rossi; Carlo Pergola; Carla Ghelardini; N Galeotti; Francesco Makovec; A Giordani; P Anzellotti; S Tacconelli; Paola Patrignani; Maurizio Anzini
Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
Current medicinal chemistry 2011;18(10):1540-54.
2010: Andrea Cappelli; Chiara Nannicini; Salvatore Valenti; Germano Giuliani; Maurizio Anzini; Laura Mennuni; Antonio Giordani; Gianfranco Caselli; Luigi Piero Stasi; Francesco Makovec; Gianluca Giorgi; Salvatore Vomero
Design, synthesis, and preliminary biological evaluation of pyrrolo[3,4-c]quinolin-1-one and oxoisoindoline derivatives as aggrecanase inhibitors.
ChemMedChem 2010;5(5):739-48.
2010: Mariangela Biava; Giulio Cesare Porretta; Giovanna Poce; Claudio Battilocchio; Fabrizio Manetti; Maurizio Botta; Stefano Forli; Lidia Sautebin; Antonietta Rossi; Carlo Pergola; Carla Ghelardini; Nicoletta Galeotti; Francesco Makovec; Antonio Giordani; Paola Anzellotti; Paola Patrignani; Maurizio Anzini
Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as anti-inflammatory and analgesic agents. Synthesis and in vitro and in vivo biological evaluation.
Journal of medicinal chemistry 2010;53(2):723-33.
2010: Maurizio Anzini; Alessia Chelini; Alessandra Mancini; Andrea Cappelli; Maria Frosini; Lorenzo Ricci; massimo valoti; Jacopo Magistretti; Loretta Castelli; Antonio Giordani; Francesco Makovec; Salvatore Vomero
Synthesis and biological evaluation of amidine, guanidine, and thiourea derivatives of 2-amino(6-trifluoromethoxy)benzothiazole as neuroprotective agents potentially useful in brain diseases.
Journal of medicinal chemistry 2010;53(2):734-44.
2010: Simone Galeazzi; Thomas M Hermans; Marco Paolino; Maurizio Anzini; Laura Mennuni; Antonio Giordani; Gianfranco Caselli; Francesco Makovec; E W Meijer; Salvatore Vomero; Andrea Cappelli
Multivalent supramolecular dendrimer-based drugs.
Biomacromolecules 2010;11(1):182-6.
2009: Lucia Lassiani; Michela V Pavan; Federico Berti; George Kokotos; Theodoros Markidis; Laura Mennuni; Francesco Makovec; Antonio Varnavas
Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand.
Bioorganic & medicinal chemistry 2009;17(6):2336-50.
2008: Marco Tafani; Luana Schito; Tahira Anwar; Manuela Indelicato; sale Patrizio; Maura Di Vito; Emanuela Morgante; Rosanna Beraldi; Francesco Makovec; Ornella Letari; Gianfranco Caselli; Corrado Spadafora; Bruna Pucci; Matteo A Russo
Induction of autophagic cell death by a novel molecule is increased by hypoxia.
Autophagy 2008;4(8):1042-53.
2008: M Rizzo; D Ventrice; F Casale; G F Caselli; Francesco Makovec
Pharmacokinetic study of a new angiotensin-AT1 antagonist by HPLC.
Journal of pharmaceutical and biomedical analysis 2008;48(2):422-7.
2008: Mariangela Biava; Giulio C Porretta; Giovanna Poce; Sibilla Supino; Fabrizio Manetti; Stefano Forli; Maurizio Botta; Lidia Sautebin; Antonietta Rossi; Carlo Pergola; Carla Ghelardini; Monica Norcini; Francesco Makovec; Antonio Giordani; Paola Anzellotti; Roberto Cirilli; Rosella Ferretti; Bruno Gallinella; Francesco La Torre; Maurizio Anzini; Paola Patrignani
Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
Bioorganic & medicinal chemistry 2008;16(17):8072-81.
2008: Maurizio Anzini; Carlo Braile; Salvatore Valenti; Andrea Cappelli; Salvatore Vomero; Luciana Marinelli; Vittorio Limongelli; Ettore Novellino; Laura Betti; Gino Giannaccini; Antonio Lucacchini; Carla Ghelardini; Monica Norcini; Francesco Makovec; Gianluca Giorgi; R Ian Fryer
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
Journal of medicinal chemistry 2008;51(15):4730-43.
2008: Maurizio Anzini; Michele Rovini; Andrea Cappelli; Salvatore Vomero; Fabrizio Manetti; Maurizio Botta; Lidia Sautebin; Antonietta Rossi; Carlo Pergola; Carla Ghelardini; Monica Norcini; Antonio Giordani; Francesco Makovec; Paola Anzellotti; Paola Patrignani; Mariangela Biava
Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity.
Journal of medicinal chemistry 2008;51(15):4476-81.
2008: Sophie Sarre; Marco Lanza; Francesco Makovec; Roberto Artusi; Gianfranco Caselli; Yvette Michotte
In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
European journal of pharmacology 2008;584(2-3):297-305.
2008: Andrea Cappelli; Chiara Nannicini; Andrea Gallelli; Germano Giuliani; Salvatore Valenti; Gal la Pericot Mohr; Maurizio Anzini; Laura Mennuni; Flora Ferrari; Gianfranco Caselli; Antonio Giordani; Walter Peris; Francesco Makovec; Gianluca Giorgi; Salvatore Vomero
Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
Journal of medicinal chemistry 2008;51(7):2137-46.
2007: Mariangela Biava; Giulio Cesare Porretta; Giovanna Poce; Sibilla Supino; Stefano Forli; Michele Rovini; Andrea Cappelli; Fabrizio Manetti; Maurizio Botta; Lidia Sautebin; Antonietta Rossi; Carlo Pergola; Carla Ghelardini; Elisa Vivoli; Francesco Makovec; Paola Anzellotti; Paola Patrignani; Maurizio Anzini
Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity.
Journal of medicinal chemistry 2007;50(22):5403-11.
2006: Andrea Cappelli; Valter Travagli; Iacopo Zanardi; Maurizio Anzini; Gianluca Giorgi; Alessandro Donati; Marianna Aggravi; Mario Casolaro; Massimo Fresta; Eugenio Paccagnini; Francesco Makovec; Salvatore Vomero
Physicochemical and biopharmaceutical characterization of endo-2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-1H-benz[e]isoindol-1-one (CR3124) a novel potent 5-HT3 receptor antagonist.
Journal of pharmaceutical sciences 2006;95(12):2706-21.
2006: Andrea Cappelli; Gal la Pericot Mohr; Germano Giuliani; Simone Galeazzi; Maurizio Anzini; Laura Mennuni; Flora Ferrari; Francesco Makovec; Eva M Kleinrath; Thierry Langer; massimo valoti; Gianluca Giorgi; Salvatore Vomero
Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
Journal of medicinal chemistry 2006;49(22):6451-64.
2006: Gabriele Losi; Marco Lanza; Francesco Makovec; Roberto Artusi; Gianfranco Caselli; Giulia Puia
Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist.
Neuropharmacology 2006;50(3):277-85.
2005: Antonio Varnavas; Lucia Lassiani; Valentina Valenta; Alessia Ciogli; Francesco Gasparrini; Laura Mennuni; Francesco Makovec
N-terminal anthranoyl-phenylalanine derivatives as CCK1 receptor antagonists: the final approach.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2005;1(5):501-17.
2005: Antonio Varnavas; Lucia Lassiani; Valentina Valenta; Laura Mennuni; Francesco Makovec; Dimitra Hadjipavlou-Litina
Anthranilic acid based CCK1 receptor antagonists: preliminary investigation on their second "touch point".
European journal of medicinal chemistry 2005;40(6):563-81.
2005: Andrea Cappelli; Andrea Gallelli; Monica Manini; Maurizio Anzini; Laura Mennuni; Francesco Makovec; M Cristina Menziani; Stefano Alcaro; Francesco Ortuso; Salvatore Vomero
Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties.
Journal of medicinal chemistry 2005;48(10):3564-75.
2005: Andrea Cappelli; Germano Giuliani; Andrea Gallelli; Salvatore Valenti; Maurizio Anzini; Laura Mennuni; Francesco Makovec; Aroldo Cupello; Salvatore Vomero
Structure-affinity relationship studies on arylpiperazine derivatives related to quipazine as serotonin transporter ligands. Molecular basis of the selectivity SERT/5HT3 receptor.
Bioorganic & medicinal chemistry 2005;13(10):3455-60.
2005: Mariangela Biava; Giulio Cesare Porretta; Andrea Cappelli; Salvatore Vomero; Fabrizio Manetti; Maurizio Botta; Lidia Sautebin; Antonietta Rossi; Francesco Makovec; Maurizio Anzini
1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.
Journal of medicinal chemistry 2005;48(9):3428-32.
2004: Flora Ferrari; Laura Mennuni; Gianfranco Caselli; Tiziano Zanelli; Francesco Makovec
Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.
European journal of pharmacology 2004;504(3):223-33.
2004: Andrea Cappelli; Gal la Pericot Mohr Gl; Andrea Gallelli; Milena Rizzo; Maurizio Anzini; Salvatore Vomero; Laura Mennuni; Flora Ferrari; Francesco Makovec; M Cristina Menziani; Pier G De Benedetti; Gianluca Giorgi
Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
Journal of medicinal chemistry 2004;47(10):2574-86.
2004: Michael Hall; Stefano Persiani; Yen-Ling Cheung; Anne Matthews; Zbigniew R Cybulski; Jeremy D Holding; Ram Kapil; Massimo D'Amato; Francesco Makovec; Lucio C Rovati
Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450.
Biopharmaceutics & drug disposition 2004;25(4):163-76.
2004: M Rizzo; D Ventrice; F Monforte; S Procopio; G De Sarro; Maurizio Anzini; Andrea Cappelli; Francesco Makovec
Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples.
Journal of pharmaceutical and biomedical analysis 2004;35(2):321-9.
2004: Colin Webber; C A Stokes; Stefano Persiani; Francesco Makovec; Alan McBurney; Ram Kapil; Brian A John; Massimo D'Amato; Leslie F Chasseaud
Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog.
European journal of drug metabolism and pharmacokinetics 2004;29(1):15-23.
2004: Antonio Varnavas; Lucia Lassiani; Valentina Valenta; Federico Berti; Andrea Tontini; Laura Mennuni; Francesco Makovec
Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept.
European journal of medicinal chemistry 2004;39(1):85-97.
2003: Andrea Cappelli; Gal la Pericot Mohr; Maurizio Anzini; Salvatore Vomero; Alessandro Donati; Mario Casolaro; Raniero Mendichi; Gianluca Giorgi; Francesco Makovec
Synthesis and characterization of a new benzofulvene polymer showing a thermoreversible polymerization behavior.
The Journal of organic chemistry 2003;68(24):9473-6.
2003: M Rizzo; Maurizio Anzini; Andrea Cappelli; Salvatore Vomero; D Ventrice; G De Sarro; S Procopio; N Costa; Francesco Makovec
Determination of a novel angiotensin-AT1 antagonist CR 3210 in biological samples by HPLC.
Farmaco (Società chimica italiana : 1989) 2003;58(9):837-44.
2003: Colin Webber; C A Stokes; Stefano Persiani; Francesco Makovec; Alan McBurney; Ram Kapil; Brian A John; Tara L Houchen; Massimo D'Amato; Leslie F Chasseaud
Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat.
European journal of drug metabolism and pharmacokinetics 2003;28(3):201-12.
2003: Colin Webber; A Roth; Stefano Persiani; AJ Peard; Francesco Makovec; Ram Kapil; Brian A John; Jeremy D Holding; Massimo D'Amato; Zbigniew R Cybulski; Leslie F Chasseaud; Lucio C Rovati
Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.
Xenobiotica; the fate of foreign compounds in biological systems 2003;33(6):625-41.
2003: Antonio Varnavas; Lucia Lassiani; Valentina Valenta; Federico Berti; Laura Mennuni; Francesco Makovec
Anthranilic acid derivatives: a new class of non-peptide CCK1 receptor antagonists.
Bioorganic & medicinal chemistry 2003;11(5):741-51.
2003: R Brodie; AJ Peard; A Roth; Stefano Persiani; Francesco Makovec; Massimo D'Amato
Development and validation of a bioanalytical method for the determination of the cholecystokinin type-1 (CCK(1)) receptor antagonist dexloxiglumide in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;784(1):91-100.
2002: Andrea Cappelli; Andrea Gallelli; Carlo Braile; Maurizio Anzini; Salvatore Vomero; Laura Mennuni; Francesco Makovec; M Cristina Menziani; Pier G De Benedetti; Alessandro Donati; Gianluca Giorgi
Novel potent 5-HT(3) receptor ligands based on the pyrrolidone structure. Effects of the quaternization of the basic nitrogen on the interaction with 5-HT(3) receptor.
Bioorganic & medicinal chemistry 2002;10(8):2681-91.
2002: Andrea Cappelli; Maurizio Anzini; Salvatore Vomero; Laura Mennuni; Francesco Makovec; Michel Hamon; Pier G De Benedetti; M Cristina Menziani
The Interactions of the 5-HT(3) receptor with arylpiperazine, tropane, and quinuclidine ligands.
Current topics in medicinal chemistry 2002;2(6):599-624.
2002: Stefano Persiani; Massimo D'Amato; Francesco Makovec; I A Tavares; P M Bishai; Lucio C Rovati
Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
International journal of clinical pharmacology and therapeutics 2002;40(5):198-206.
2002: Andrea Cappelli; Maurizio Anzini; Salvatore Vomero; Laura Mennuni; Francesco Makovec; Edith Doucet; Michel Hamon; M Cristina Menziani; Pier G De Benedetti; Gianluca Giorgi; Carla Ghelardini; Simona Collina
Novel potent 5-HT(3) receptor ligands based on the pyrrolidone structure: synthesis, biological evaluation, and computational rationalization of the ligand-receptor interaction modalities.
Bioorganic & medicinal chemistry 2002;10(3):779-801.
2001: MA Maselli; AL Piepoli; Francesco Pezzolla; Vito Guerra; Maria Lucia Caruso; Laura Mennuni; Dionigi Lorusso; Francesco Makovec
Effect of three nonpeptide cholecystokinin antagonists on human isolated gallbladder.
Digestive diseases and sciences 2001;46(12):2773-8.
2001: Stefano Persiani; Massimo D'Amato; Francesco Makovec; S H Arshad; S T Holgate; Lucio C Rovati
Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients.
Biopharmaceutics & drug disposition 2001;22(2):73-81.
2000: Marco Lanza; Francesco Makovec
Cholecystokinin (CCK) increases GABA release in the rat anterior nucleus accumbens via CCK(B) receptors located on glutamatergic interneurons.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(1):33-8.
1999: L Revel; Francesco Makovec
Discovery of new CCK2 receptor antagonists. A review of pharmacological studies. Part I: Development of potential therapeutic tools for gastrin-related gastrointestinal diseases.
Methods and findings in experimental and clinical pharmacology 1999;21(5):375-83.
1999: Andrea Cappelli; Maurizio Anzini; Salvatore Vomero; L Canullo; Laura Mennuni; Francesco Makovec; Edith Doucet; Michel Hamon; M Cristina Menziani; Pier G De Benedetti; Giancarlo Bruni; M R Romeo; Gianluca Giorgi; Alessandro Donati
Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Journal of medicinal chemistry 1999;42(9):1556-75.
1999: Francesco Makovec; L Revel; O Letari; Laura Mennuni; M Impicciatore
Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
European journal of pharmacology 1999;369(1):81-90.
1998: L Revel; Laura Mennuni; P Garofalo; Francesco Makovec
CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.
Behavioural pharmacology 1998;9(3):183-94.
1998: Andrea Cappelli; Maurizio Anzini; Salvatore Vomero; Laura Mennuni; Francesco Makovec; Edith Doucet; Michel Hamon; Giancarlo Bruni; M R Romeo; M Cristina Menziani; Pier G De Benedetti; Thierry Langer
Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
Journal of medicinal chemistry 1998;41(5):728-41.
1997: Marco Lanza; C Bonnafous; S Colombo; L Revel; Francesco Makovec
Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex.
Neuropharmacology 1997;36(8):1057-64.
1996: P Garofalo; S Colombo; M Lanza; L Revel; Francesco Makovec
CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory in rats and mice.
The Journal of pharmacy and pharmacology 1996;48(12):1290-7.
1996: O Letari; Laura Mennuni; L Revel; S Colombo; Francesco Makovec
Cytosolic Ca2+ evaluation in rabbit parietal cells: a novel method to screen gastrin receptor antagonists.
European journal of pharmacology 1996;306(1-3):325-33.
1996: Francesco Makovec; W Peris; S Frigerio; R Giovanetti; O Letari; Laura Mennuni; L Revel
Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives.
Journal of medicinal chemistry 1996;39(1):135-42.
1994: Lucio C Rovati; M D'Amato; W Peris; L Revel; Francesco Makovec
Selectivity and potency of new basic CCK-B antagonists.
Annals of the New York Academy of Sciences 1994;713():395-7.
1992: L Revel; S Colombo; F Ferrari; G Folco; Lucio C Rovati; Francesco Makovec
CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma.
European journal of pharmacology 1992;229(1):45-53.
1992: Francesco Makovec; W Peris; L Revel; R Giovanetti; D Redaelli; Lucio C Rovati
Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
Journal of medicinal chemistry 1992;35(20):3633-40.
1992: L Revel; F Ferrari; Francesco Makovec; Lucio C Rovati; M Impicciatore
Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative.
European journal of pharmacology 1992;216(2):217-24.
1992: Susan A Watson; D M Crosbee; D L Morris; J F Robertson; Francesco Makovec; Lucio C Rovati; Jack D Hardcastle
Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth.
British journal of cancer 1992;65(6):879-83.
1992: Francesco Makovec; W Peris; L Revel; R Giovanetti; Laura Mennuni; Lucio C Rovati
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
Journal of medicinal chemistry 1992;35(1):28-38.
1989: Ivo Setnikar; R Cereda; M A Pacini; L Revel; Francesco Makovec
Pharmacological characterisation of the smooth muscle antispasmodic agent tiropramide.
Arzneimittel-Forschung 1989;39(9):1114-9.
1989: Ivo Setnikar; R Cereda; M A Pacini; L Revel; Francesco Makovec
Antispasmodic activity of tiropramide.
Arzneimittel-Forschung 1989;39(9):1109-14.
1989: Ivo Setnikar; Francesco Makovec; R Chistè; C Giachetti; G Zanolo
Distribution of tiropramide and metabolites after single intravenous or peroral administration of 14C-tiropramide to the rat.
Arzneimittel-Forschung 1989;39(5):579-86.
1989: Ivo Setnikar; Francesco Makovec; R Chistè; C Giachetti; G Zanolo
Metabolism and excretion of 14C-tiropramide after single intravenous or peroral administration to the rat.
Arzneimittel-Forschung 1989;39(3):328-34.
1988: Ivo Setnikar; Francesco Makovec; R Chistè; C Giachetti; G Zanolo
Tiropramide and metabolites in blood and plasma after intravenous or peroral administration of 14C-tiropramide to the rat.
Arzneimittel-Forschung 1988;38(12):1815-9.
1988: Ivo Setnikar; R Chisté; Francesco Makovec; Lucio C Rovati; S J Warrington
Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.
Arzneimittel-Forschung 1988;38(5):716-20.
1988: B Balboni; P Valenti; P Da Re; L C Rovati; Francesco Makovec
Calcium antagonists: vinylogues and bivalent ligands related to nifedipine.
Die Pharmazie 1988;43(5):318-20.
1988: R Arigoni; R Chistè; Francesco Makovec; Ivo Setnikar; E Benfenati; R Fanelli
Identification of metabolites of tiropramide in human urine.
Biomedical & environmental mass spectrometry 1988;15(4):205-9.
1987: Francesco Makovec; M Bani; R Cereda; R Chisté; M A Pacini; L Revel; L A Rovati; Lucio C Rovati; Ivo Setnikar
Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
Arzneimittel-Forschung 1987;37(11):1265-8.
1987: Ivo Setnikar; M Bani; R Cereda; R Chisté; Francesco Makovec; M A Pacini; L Revel
Loxiglumide protects against experimental pancreatitis.
Arzneimittel-Forschung 1987;37(10):1172-4.
1987: Ivo Setnikar; M Bani; R Cereda; R Chisté; Francesco Makovec; M A Pacini; L Revel
Anticholecystokinin activities of loxiglumide.
Arzneimittel-Forschung 1987;37(10):1168-71.
1987: Francesco Makovec; R Chisté; W Peris; Ivo Setnikar
Pharmacokinetics and metabolism of [14C]-proglumetacin after oral administration in the rat.
Arzneimittel-Forschung 1987;37(7):806-13.
1987: Ivo Setnikar; M Bani; R Cereda; R Chisté; Francesco Makovec; M A Pacini; L Revel; Lucio C Rovati; L A Rovati
Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist.
Arzneimittel-Forschung 1987;37(6):703-7.
1987: Ivo Setnikar; R Arigoni; R Chisté; Francesco Makovec; L Revel
Plasma levels of proglumetacin and its metabolites after intravenous or oral administration in the dog.
Arzneimittel-Forschung 1987;37(6):698-702.
1987: Francesco Makovec; M Bani; R Cereda; R Chistè; M A Pacini; L Revel; Lucio C Rovati
Antispasmodic activity on the gallbladder of the mouse of CR 1409 (lorglumide) a potent antagonist of peripheral CCK.
Pharmacological research communications 1987;19(1):41-51.
1986: Francesco Makovec; M Bani; R Chistè; L Revel; Lucio C Rovati; Ivo Setnikar
Different peripheral and central antagonistic activity of new glutaramic acid derivatives on satiety induced by cholecystokinin in rats.
Regulatory peptides 1986;16(3-4):281-90.
1986: Francesco Makovec; M Bani; R Cereda; R Chistè; L Revel; Lucio C Rovati; Ivo Setnikar; L A Rovati
Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice.
Peptides 1986;7(6):1159-64.
1986: R Arigoni; R Chisté; A Drovanti; Francesco Makovec; P Senin; Ivo Setnikar
Pharmacokinetics of tiropramide after single doses in man.
Arzneimittel-Forschung 1986;36(4):738-44.
1986: Francesco Makovec; M Bani; R Chisté; L Revel; Lucio C Rovati; L A Rovati
Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity.
Arzneimittel-Forschung 1986;36(1):98-102.
1985: Francesco Makovec; R Chistè; M Bani; M A Pacini; Ivo Setnikar; L A Rovati
New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity.
Arzneimittel-Forschung 1985;35(7):1048-51.